Non-contraceptive benefits of hormonal contraception

2019 ◽  
Vol 1 (8) ◽  
pp. 394-399
Author(s):  
Michelle Cooper ◽  
Katie Boog
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Premenstrual Syndrome ◽  
Polycystic Ovary ◽  
Hormonal Contraception ◽  
Hormonal Contraceptives ◽  
Primary Role ◽  
Menstrual Pain ◽  
Ovary Syndrome ◽  
Risk Of Cancer

Beyond their primary role of preventing pregnancy, hormonal contraceptives provide a number of non-contraceptive benefits including a reduction in menstrual pain and bleeding, improvement in acne and a decrease in the lifetime risk of cancer of the ovaries and endometrium. They are also widely used in the management of a number of gynaecological conditions including endometriosis, premenstrual syndrome and polycystic ovary syndrome. Although the risks may outweigh the benefits when a method is used solely for contraception, the risk-benefit profile may change when it is also used for a medical indication. Potential non-contraceptive benefits should be discussed with all women when considering the most appropriate form of contraception to suit their needs.

Non-contraceptive benefits of hormonal contraception

2019 ◽  
Vol 30 (11) ◽  
pp. 528-535
Author(s):  
Michelle Cooper ◽  
Katie Boog
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Premenstrual Syndrome ◽  
Polycystic Ovary ◽  
Hormonal Contraception ◽  
Hormonal Contraceptives ◽  
Primary Role ◽  
Menstrual Pain ◽  
Ovary Syndrome ◽  
Risk Of Cancer

Hormonal contraception can provide reliable protection against unintended pregnancy, as well as a broad range of non-contraceptive benefits. Dr Michelle Cooper and Dr Katie Boog give an overview of these benefits Beyond their primary role of preventing pregnancy, hormonal contraceptives provide a number of non-contraceptive benefits including a reduction in menstrual pain and bleeding, improvement in acne and a decrease in the lifetime risk of cancer of the ovaries and endometrium. They are also widely used in the management of a number of gynaecological conditions including endometriosis, premenstrual syndrome and polycystic ovary syndrome. Although the risks may outweigh the benefits when a method is used solely for contraception, the risk-benefit profile may change when it is also used for a medical indication. Potential non-contraceptive benefits should be discussed with all women when considering the most appropriate form of contraception to suit their needs.

Hypercoagulable disorders in polycystic ovary syndrome: myth or reality?

2020 ◽  
Vol 19 (6) ◽  
pp. 60-68
Author(s):  
Yu.A. Koloda ◽  
◽  
N.M. Podzolkova ◽  
Yu.G. Petrichenko ◽  
◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Hormonal Contraception ◽  
Ovary Syndrome ◽  
Art Programs ◽  
Total Life Expectancy ◽  
Venous Thromboembolic ◽  
The Impact ◽  
The Relationship

A review of studies on the features of the hemostasis system in patients with polycystic ovary syndrome (PCOS), the relationship between hypercoagulable disorders and PCOS, including on the background of additional risk factors. The data on the risk of venous thromboembolic complications in patients with PCOS at different age periods against hormonal contraception and in ART programs are presented. The possible role of hypercoagulable disorders in the prevention of pregnancy in patients with PCOS is discussed. The data on the impact of PCOS on total life expectancy and on the main causes of death in case of this disease are also provided. Key words: pregnancy, venous thromboembolism, hypercoagulable disorders, strokes, polycystic ovary syndrome, combined oral contraceptives, assisted reproductive technology programs, ovarian hyperstimulation syndrome, cardiovascular diseases

The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review

2020 ◽  
pp. 1-8
Author(s):  
Daniela Menichini ◽  
Gianpiero Forte ◽  
Beatrice Orrù ◽  
Giuseppe Gullo ◽  
Vittorio Unfer ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Embryo Quality ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Endometrial Receptivity ◽  
Metabolic Disturbances ◽  
Ovary Syndrome ◽  
Beneficial Role

Abstract. Vitamin D is a secosteroid hormone that plays a pivotal role in several metabolic and reproductive pathways in humans. Increasing evidence supports the role of vitamin D deficiency in metabolic disturbances and infertility in women with polycystic ovary syndrome (PCOS). Indeed, supplementation with vitamin D seems to have a beneficial role on insulin resistance and endometrial receptivity. On the other hand, exceedingly high levels of vitamin D appear to play a detrimental role on oocytes development and embryo quality. In the current review, we summarize the available evidence about the topic, aiming to suggest the best supplementation strategy in women with PCOS or, more generally, in those with metabolic disturbances and infertility. Based on the retrieved data, vitamin D seems to have a beneficial role on IR, insulin sensitivity and endometrial receptivity, but high levels and incorrect timing of administration seem to have a detrimental role on oocytes development and embryo quality. Therefore, we encourage a low dose supplementation (400–800 IU/day) particularly in vitamin D deficient women that present metabolic disturbances like PCOS. As far as the reproductive health, we advise vitamin D supplementation in selected populations, only during specific moments of the ovarian cycle, to support the luteal phase. However, ambiguities about dosage and timing of the supplementation still emerge from the clinical studies published to date and further studies are required.

scholarly journals The role of serum β-trophin and endostatin in patients with polycystic ovary syndrome: Are they correlated?

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Wei Gong ◽  
Aikmu Bilixzi ◽  
Xinmei Wang ◽  
Yanli Lu ◽  
Li Wan ◽  
...  
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Influencing Factors ◽  
Polycystic Ovary ◽  
Pearson Correlation ◽  
Healthy Controls ◽  
Newly Diagnosed ◽  
Ovary Syndrome ◽  
Factors Affecting ◽  
Main Factors

Abstract Background It’s necessary to investigate the serum β-trophin and endostatin (ES) level and its influencing factors in patients with newly diagnosed polycystic ovary syndrome (PCOS). Methods Newly diagnosed PCOS patients treated in our hospital were selected, and healthy women who took physical examination during the same period as healthy controls. We detected and compared the related serum indicators between two groups, Pearson correlation were conducted to identify the factors associated with β-trophin and ES, and the influencing factors of β-trophin and ES were analyzed by logistic regression. Results A total of 62 PCOS patients and 65 healthy controls were included. The BMI, WHI, LH, FSH, TT, FAI, FBG, FINS, HOMA-IR, TC, TG, LDL, ES in PCOS patients were significantly higher than that of healthy controls, while the SHBG and HDL in PCOS patients were significantly lower than that of healthy controls (all p < 0.05). β-trophin was closely associated with BMI (r = 0.427), WHR (r = 0.504), FBG (r = 0.385), TG (r = 0.405) and LDL (r = 0.302, all p < 0.05), and ES was closely associated with BMI (r = 0.358), WHR (r = 0.421), FBG (r = 0.343), TC (r = 0.319), TG (r = 0.404, all p < 0.05). TG, BMI, WHR and FBG were the main factors affecting the serum β-trophin levels (all p < 0.05). FBG, TC and BMI were the main factors affecting the serum ES levels (all p < 0.05). The TG, β-trophin, ES level in PCOS patients with insulin resistance (IR) were significantly higher than that of those without IR (all p < 0.05). Conclusion Increased β-trophin is closely associated with increased ES in patients with PCOS, which may be the useful indicators for the management of PCOS.

Sign in / Sign up

Export Citation Format

Share Document